A collection of the latest publications on hyperhidrosis
Case of miliaria rubra histologically showing neutrophilic eccrine hidradenitis due to hyperhidrosis induced by a catecholamine-producing neuroblastoma.
J Dermatol. 2020 Jan 07;:
Authors: Katayama S, Iwata H, Nomura Y, Nakamura A, Yamaguchi T, Hishimura N, Nakayama K, Hashimoto K, Honda S, Shimizu H
PMID: 31912533 [PubMed – as supplied by publisher]
| Related Articles |
Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis.
Ir J Med Sci. 2020 Jan 03;:
Authors: Lynch OE, Aherne T, Gibbons J, Boland MR, Ryan ÉJ, Boyle E, Egan B, Tierney S
Abstract
BACKGROUND: Axillary hyperhidrosis is a common complaint affecting 5% of the general population. It can significantly impact quality of life (QOL) and may be extremely debilitating. Administration of intra-dermal botulinum toxin type-A (Botox) has been proven to be effective in managing axillary hyperhidrosis; however, to date, no long-term data has assessed its efficacy.
AIM: We aim to assess long-term (> 5 years) QOL outcomes in this patient cohort.
METHODS: In this single-centre series, all patients attending for axillary botox, with five or more years of follow-up, were prospectively included. QOL was assessed in all patients using the validated assessment tool, the modified Dermatology Life Quality Index (DLQI). Standard statistical methods were utilised with data reported as mean (± standard deviation). Subgroup analysis utilising previously published departmental data allowed for further assessment of change in QOL over time.
RESULTS: A total of 75 patients (83% female) met the inclusion criteria with 67% completing the DLQI assessment. Follow-up ranged from 5 to 10 years with a mean age of 37.6 years (± 8.82). The mean number of treatments over the study period was 12 (± 3.1). Mean overall post-treatment DLQI score was 1.6 (± 2.01). This represented a significant improvement in patient QOL (p = < 0.0001) associated with long-term botox application. This statistical significance was identified consistently across all components of the DLQI tool.
CONCLUSION: These data suggest that the established early QOL benefits associated with intra-dermal botox administration for AH are sustained in the long term. This benefit was seen across all subsets of the DLQI tool.
PMID: 31898163 [PubMed – as supplied by publisher]
 |
Related Articles |
Thoracoscopic sympathotomy for palmar hyperhidrosis: How young is too young?
J Pediatr Surg. 2019 Dec 11;:
Authors: Vasconcelos-Castro S, Soares-Oliveira M, Tuna T, Borges-Dias M
Abstract
BACKGROUND/PURPOSE: Primary hyperhidrosis affects 1%-3% of the general population, with increased incidence in teenagers, having an important impact in the quality of life. This study evaluates the efficacy and patients’ satisfaction after bilateral thoracoscopic sympathotomy.
METHODS: Retrospective analysis of pediatric patients with palmar primary hyperhidrosis that underwent bilateral thoracoscopic sympathotomy over the last eight years. The procedure was performed with 2 ports and simple transection of the sympathetic chain. Pre and postoperative sweating severity was evaluated by telephone interview, using the Hyperhidrosis Disease Severity Scale (HDSS).
RESULTS: 23 patients (19 girls; 15.5 [11-19] years-old) underwent bilateral thoracoscopic sympathotomy. All complained of palmar hyperhidrosis, which resolved in all cases. Compensatory sweating occurred in 47.8% of patients. 21 patients answered the telephone interview: all of them would recommend the surgery to others. Sweating severity improved in all patients, with a mean decrease of 1.95 values of the HDSS from preoperative to postoperative evaluation (p < 0.05). There was neither morbidity nor mortality.
CONCLUSIONS: Bilateral thoracoscopic sympathotomy is a safe and effective treatment for primary palmar hyperhidrosis. Being the first report on pediatric application of HDSS, we conclude that children are very satisfied with the final outcome.
TYPE OF STUDY: Treatment study.
LEVEL OF EVIDENCE: Level III.
PMID: 31870560 [PubMed – as supplied by publisher]
 |
Related Articles |
The Meaning of Living for Men Suffering From Primary Hyperhidrosis.
Am J Mens Health. 2019 Nov-Dec;13(6):1557988319892725
Authors: Shayesteh A, Brulin C, Nylander E
Abstract
Primary hyperhidrosis means excessive focal sweating and it has a negative effect on the mental health of those affected. Although there is no gender difference regarding the prevalence of the disease, men are less likely to seek help for this condition. The aim of this study was to explore the meaning of living with primary hyperhidrosis in men. Interviews with 15 men, selected by purposive sampling, were performed at Umeå University Hospital in Sweden between June 2016 and October 2017, and analyzed using qualitative content analysis technique according to Graneheim and Lundman (2004). This study found one theme, namely, to be captured in a filthy body, based on the categories: surrender to the condition reluctantly; prepare for a sweat attack; withdraw from close contacts; and worry about others’ perceptions. The theme describes men living with hyperhidrosis feeling filthy while they struggle to control or hide the excessive sweating. Insufficient understanding from others and being reminded from the sweating is stressful and results in a sense of captivity. Interpreting the result, we conclude that the disease could stigmatize the individual, which has a negative effect on mental health and the will to seek help. Meanwhile, providing information about the disease early, as in schools, could increase the willingness of men to seek medical help. The results of this study also reinforce quantitative studies reporting the negative effects of primary hyperhidrosis on mental health.
PMID: 31849276 [PubMed – in process]
| |
Related Articles |
Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.
J Am Acad Dermatol. 2019 Dec 14;:
Authors: Siscos SM, Figenshau K, Rajpara A
PMID: 31846717 [PubMed – as supplied by publisher]
| Related Articles |
Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis.
Can J Ophthalmol. 2019 Dec;54(6):e300-e302
Authors: Pashaei-Marandi A, Assam JH, Arnold A, Lee AG, Bonelli L
PMID: 31836120 [PubMed – in process]
 |
Related Articles |
Association of Primary Hyperhidrosis with Depression and Anxiety: A Systematic Review.
Acta Derm Venereol. 2019 Dec 10;:
Authors: Kristensen JK, Vestergaard DG, Swartling C, Bygum A
PMID: 31821514 [PubMed – as supplied by publisher]
| |
Related Articles |
Botulinum Toxin: Pharmacology and Injectable Administration for the Treatment of Primary Hyperhidrosis.
J Am Acad Dermatol. 2019 Dec 04;:
Authors: Nawrocki S, Cha J
Abstract
Hyperhidrosis is a dermatological condition defined by excessive sweating beyond thermoregulatory needs with significant effects on patients’ quality of life. Hyperhidrosis is categorized as primary or secondary: primary hyperhidrosis is mostly focal and idiopathic, whereas secondary hyperhidrosis is commonly generalized and caused by an underlying medical condition or use of medications. Various surgical and nonsurgical therapies exist for primary hyperhidrosis. Although botulinum toxin is one of the deadliest toxins known, when used in small doses, it is one of the most effective therapies for primary hyperhidrosis. Botulinum toxin injections are widely used as a second-line primary hyperhidrosis treatment option, when topical treatment strategies have failed. This article provides an overview of the commercially available botulinum toxin formulations and their applications for the treatment of primary hyperhidrosis.
PMID: 31811879 [PubMed – as supplied by publisher]
| Related Articles |
Hyperhidrosis Prevalence: A Disease Underreported by Patients and Underdiagnosed by Physicians.
Indian Dermatol Online J. 2019 Nov-Dec;10(6):676-681
Authors: Wadhawa S, Agrawal S, Chaudhary M, Sharma S
Abstract
Background: Hyperhidrosis (HH) is a disorder characterized by excessive sweating beyond required for normal thermoregulation, as a result of the excessive functioning of the sudomotor sweat control system. HH is broadly classified into 2 categories: primary HH and secondary. Our aim was to study the prevalence of HH in patients attending dermatological outpatients.
Methods: Randomly selected 832 attendees of dermatology outpatient department were requested to fill out a questionnaire for their presenting concerns to attend, the demography information (age, gender, and occupation), and presence of excessive visible sweating symptoms after the informed, written, and understood consent. This questionnaire was then evaluated by the researchers. And those who had a history of excessive sweating were evaluated in detail about HH by another questionnaire.
Results: The overall prevalence of HH was 17.9% (149/832), whereas only self-reported prevalence was 10.2% (85/832) in the dermatology outpatients. Of 149 patients, 110 (73.8%) were of primary HH followed by 39 (26.2%) of secondary HH.
Conclusion: This study showed a higher prevalence of HH in the attendees of dermatology outpatients of a tertiary care center but estimates that this disease affects a much larger proportion of individuals in the Nepalese population.
PMID: 31807447 [PubMed]
| Related Articles |
Effects of Direct Current Administration on Hyperhidrosis Disease Severity Scale in Patients with Axillary Hyperhidrosis.
Biomed Res Int. 2019;2019:3232015
Authors: Şener S, Karakoç Y
Abstract
Background: Focal hyperhidrosis mostly affects the axillae, hands, feet, and face. For the management, several techniques are used. The aim of this study was to investigate the effects of direct current administration on the hyperhidrosis disease severity scale (HDSS) in patients with axillary hyperhidrosis that have various HDSS scores.
Design and Setting: Original article, University Hospital.
Methods: Sixty patients with primary axillary hyperhidrosis were inquired about the HDSS scores and the scores were noted at the onset and at the end of the 10th application. One month after the last session, HDSS scores were also inquired. At the end of 1-month follow-up, the patients whose HDSS scores rose after the 10th session were accepted as nonresponder. For the current delivery, a new iontophoresis application module (Sweat CureR) designed by Dr. Karakoc was used.
Results: Direct current application decreased axillary sweat intensity by 70% at both sides, and lowered the HDSS by about 1.5 degree. Major reduction in sweat intensity was in the patients with low HDSS scores (75%). Negative correlation was found between initial HDSS scores and median values of decreased sweat intensity (r = -0.317, p = 0.022). Minimal temporary side effects including skin irritation and one or more vesicle formation were inspected in 29 patients and, the permanent punctual pigmentation was observed only in one patient.
Conclusions: Decrease in axillary hyperhidrosis is satisfactory for these patients. Since iontophoresis application has beneficial effect and minimal side effects, it should be recommended to the patients before advanced management or surgical techniques.
PMID: 31781610 [PubMed – in process]